Table 3: Prevalence (95% confidence interval) of the metabolic syndrome by the JIS, IDF, and ATPIII 2005 criteria presented by gender and HIV-related subgroups.

SubgroupsJIS valueIDF valueATPIII 2005 value

Gender ()
Overall28.2 (25.0–31.4)<0.00126.5 (23.3–29.6)<0.00124.1 (21.0–27.1)<0.001
Men16.6 (10.8–22.4)11.5 (6.5–16.5)13.4 (8.1–18.7)
Women31.3 (27.6–35.0)30.5 (26.8–34.2)26.9 (23.3–30.5)

HIV duration ()
Overall27.8 (24.6–31.1)0.00226.1 (22.9–29.2)0.00323.7 (20.6–26.7)0.001
 yrs22.5 (18.1–26.9)21.0 (16.8–25.3)17.9 (13.8–21.9)
 yrs32.6 (27.9–37.2)30.5 (26.0–35.1)28.8 (24.3–33.2)

CD4 count ()
Overall29 (24.4–33.6)0.11828.4 (23.8–33)0.11525.2 (20.8–29.6)0.060
CD4 25.3 (19.0–31.5)24.7 (18.5–30.9)21.0 (15.1–26.8)
CD4 32.6 (25.9–39.3)32.1 (25.4–38.8)29.4 (22.9–35.9)

ART use ()
Overall28.0 (24.7–31.4)0.29226.2 (22.9–29.4)0.30524.3 (21.1–27.5)0.175
No ART34.8 (21.0–48.6)32.6 (19.1–46.2)32.6 (19.1–46.2)
On ART27.6 (24.1–31.0)25.7 (22.4–29.1)23.7 (20.5–27.0)
ART regimens0.0170.0310.039
1st line23.9 (19.9–28.0)22.5 (18.6–26.5)20.7 (16.8–24.5)
2nd line32.9 (22.5–43.3)29.1 (19.1–39.1)30.4 (20.2–40.5)
Others35.1 (27.4–42.8)33.1 (25.5–40.7)29.1 (21.7–36.4)

Data are percentage and 95% confidence intervals; ATPIII: Adult Treatment Panel III; EGIR: European Group for the Study of Insulin Resistance; IDF: International Diabetes Federation; JIS: Joint Interim Statement; HIV: human immunodeficiency virus; ART: antiretroviral therapy. Data were missing for some characteristics. For each grouping variable for which data were missing for some participants, the number of participants with valid data is provided (attached to the name of the variable), as well as the overall prevalence of metabolic syndrome in that subsample.